Aura Biosciences, Inc.
Financials
Valuation Metrics
Aura Biosciences, Inc.'s Market Cap is $666M. At end of 2025 it was $359M. Ranked #2659 of 3,121 in US market (top 85%), #1135 of 1,463 on NASDAQ (top 78%), #210 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 79%) by Market Cap.
Investment Metrics(as of 2026-09-19)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $666M | US#2,659/3,121 Sec#210/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-131M | US—/3,121 Sec—/266 |
| Total Assets | $348M | US#2,885/3,121 Sec#200/266 |
| Net Assets | $315M | US#2,502/3,121 Sec#156/266 |
| Employees | 113 | US#2,603/3,121 Sec#168/266 |
| Value | ||
| P/B | 2.11x | US#1,346/3,121 Sec#57/266 |
| FCF Yield | -15.42% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -41.56% | US#2,639/3,121 Sec#139/266 |
| ROA | -37.63% | US#2,936/3,121 Sec#182/266 |
| Financial Health | ||
| Debt Ratio | 10.42% | US#117/3,121 Sec#52/266 |
| Total Debt | $17M | US#2,781/3,121 Sec#194/266 |
| FCF | $-103M | US#2,633/3,121 Sec#146/266 |
| Cash | $68M | US#2,444/3,121 Sec#206/266 |
| Current Ratio | 16.82x | US#146/3,121 Sec#38/266 |
| Performance | ||
| 1Y Return | 2.88% | US#1,520/3,121 Sec#172/266 |
| 1M Return | -17.33% | US#2,954/3,121 Sec#238/266 |
| From 52W High | -32.49% | US#2,112/3,121 Sec#166/266 |
| 1Y MDD | -31.24% | US#1,509/3,121 Sec#97/266 |
| Trading | ||
| Volume | 3,166,587 shares | US#1,489/3,121 Sec#162/266 |
| Trading Value | $21M | US#2,598/3,121 Sec#216/266 |
| Per Share | ||
| EPS | $-1.27 | US—/3,121 Sec—/266 |
| BPS | $3.05 | US#2,490/3,121 Sec#163/266 |
Company Info
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.